Track topics on Twitter Track topics that are important to you
Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD is once again flexing its product’s muscles, this time unveiling that the anti-PD-1 drug has excelled in combination with chemotherapy in the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC).
Original Article: Keytruda success continues, beating Opdivo in lung cancer survivalNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...